As part of our strategy to improve our product of electronic prescription, Delonia and ViDAL Vademecum have reached an agreement on a collaboration agreement through which ViDAL Vademecum’s pharmacological information and clinical decision support functions are incorporated into the digital prescription itself. It is a unique, integrated solution designed to optimize the care provided by hospitals and healthcare professionals.
eReceta is Delonia’s approved electronic prescription system, with double certification of the Prescription and Repository system according to the requirements of the General Councils of Physicians, Dentists, Podiatrists and Pharmacists. As such, it is interoperable and connects the three parties involved in the prescription process, professional, patient and pharmacy, with all the guarantees of security in the handling of health data.
So far, in its vocation to simplify care processes as much as possible, Delonia’s electronic prescription was different from other similar solutions because of its high level of customization and advanced configuration. In addition, it guarantees the total adequacy of the prescriber’s front end, facilitating integration with the support systems of hospitals, centers and healthcare professionals. To these elements, we must now add the integration of ViDAL Vademecum’s clinical intelligence systems.
eReceta Delonia-ViDAL is a unique, integrated solution designed to optimize the care provided by hospitals and healthcare professionals.
ViDAL Group is Europe’s leading company in health informatics and information systems for online access to drug databases and evidence-based information. As such, it is the first European Pharmacological Knowledge CDS provider to obtain the Class IIb MDR CE marking for its medical device for the analysis of prescriptions, dispensing and administrations.
This certification is further proof of the reliability of VIDAL’s solutions for healthcare professionals and its commitment to the quality control of its technologies. The “ViDAL Sécurisation” technology is used to report the hazards and risks associated with a given patient’s medication prescriptions. For Class IIb CE marking, the positive impact on patient health status has been demonstrated by a real data study analyzing the reduction of inappropriate prescriptions.
ViDAL Vademecum is the first European Pharmacological Knowledge CDS provider to obtain the CE marking class IIb MDR for its medical device for prescription analysis, dispensing and administration.
The ViDAL Vademecum database includes complete reference information on marketed medicines and hospital pharmacotherapeutics. Backed by more than 100 years of experience in the field of drug information, its application improves patient safety by providing healthcare professionals with reliable medical and scientific information. In addition, its Clinical Decision Support Modules provide a wide range of alerts on various risks associated with medication. This enables healthcare professionals to more reliably determine which treatment is most appropriate for a patient.
From November 2023, Delonia and ViDAL Vademecum will provide hospitals, centres and healthcare professionals with a solution that combines the functionality of electronic prescriptions with the best and most complete information and therapeutic decision support. It is a highly usable solution, with full customization and integration options in hospital, clinic and insurance management software, and with the capacity to expand and adapt its functionalities to the specific needs of each client.
With this solution, at the time of prescription, the professional will have the functionality of drug selection, dosage and online digital prescription and all the pharmacological information of ViDAL. All this with easy access to all available drug references on-site, as well as to the alarm system integrated in the prescription itself. With the information on the patient, the medication and the dosage, the professional can be alerted about contraindications, interactions, problems with dosage levels, drug allergies and detection of duplicate therapies, among others.
Since November 2023, Delonia and ViDAL Vademecum have made available to hospitals, centers and healthcare professionals a solution that combines the functionality of electronic prescriptions with the best and most complete information and therapeutic decision support.
A highly efficient cutting-edge tool, designed to make the work of medical professionals and hospitals easier and safer, in a digital and online environment at the forefront of medical technology. This Delonia-ViDAL Alliance, supported by VIDAL certifications (ISO 13485:2016 certification and Class IIb CE marking) provides eReceta users (patients, healthcare professionals, Healthcare Institutions) with additional guarantees of quality and compliance with current regulatory requirements.
For more information, please contact us:
- Delonia: Amelia Uceda (email@example.com)
- ViDAL Vademecum: Manuel Júlbez (firstname.lastname@example.org)
Or access the system and request a free trial to see all the benefits for yourself.